# US 2012/0142731 A1 · Methods of inhibiting viral infection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0142731 A1
- Document ID: US20120142731A1
- Status: Published application
- Kind: A1
- Application number: 12/261,603
- Filed: 2008-10-30
- Published: 2012-06-07
- Earliest claimed: 2007-10-31
- Assignees: Functional Genetics, Inc.
- Inventors: Michael Kinch; Michael Goldblatt
- Web page: https://patentgrep.com/patent/US20120142731A1

## CPC

- C07D 215/44: with aryl radicals attached to said nitrogen atoms
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 31/16: for influenza or rhinoviruses
- A61P 31/18: for HIV
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds, pharmaceutical compositions and methods of inhibiting viral infection in a mammal in need of same, are provided, which employ compounds of the formula wherein each X is independently H or an electrodonating group, each Y is independently H, alkyl of 1-4 carbon atoms, hydroxy, alkoxy or methylene and wherein Substituent Z is a di-or-tri akly amino, or alkyl di or tri amino, optionally substituted with a halogen moiety. This family of compounds, designated FGI-104 herein, inhibits viral infection therapeutically and prophylactically.

## Claims

### Claim 1

A compound of the formula
wherein each substituent X is independently H or an electron donating group, which may be selected from the group including chloro chloro or other halogen, hydroxy, alkoxy (—OR), aryloxy (—OAr), trialkylammonium (—NR3+), alkylamido (—NHCOR, —NRCOR′), arylamido (—NHCOAr, —NRCOAr, —NArCOAr), arylcarbamoyl (—NHCOOAr, —NRCOOAr), alkylcarbamoyl (—NHCOOR, —NRCOOR′), cyano (—CN), nitro (—NO2), ester (—COOR, —COOAr), or alkyl halo, each substituent Y is independently H, alkyl of 1-4 carbon atoms, hydroxy, alkoxy oe methylene and wherein
substituent Z is a di-or-tri akly amino, or alkyl di or tri amino, optionally substituted with a halogen moiety,
further wherein said compound, when administered in effective amounts to a mammalian cell infected with a virus, inhibits viral infection and replication in said cell without cytotoxic effects for said cell.

### Claim 2 (depends on 1)

The compound of claim 1, wherein said compound is selected from the group consisting of R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, R25, R26, R27, R28, R29, R30, R31 and R32.

### Claim 3 (depends on 2)

The compound of claim 2, wherein said compound is R19 or R24.

### Claim 4 (depends on 3)

The compound of claim 3, wherein said compound is R24.

### Claim 5 (depends on 1)

A method of treating viral infection in a mammalian cell, comprising administering an effective amount of a compound of claim 1 to said cell, therapeutically or prophylactically, wherein said virus is Ebola virus, Marburg virus, human immunodeficiency virus (HIV), Hepatitis B virus (HBV), Hepatitis C virus (HCV), Dengue fever virus, porcine reproductive and respiratory syndrome (PRRS) virus, bovine corona virus, influenza virus, an alphavirus, cowpox virus, West Nile virus, respiratory syncytial virus (RSV), parainfluenza virus (PIV), Human metapneumovirus (HMPV) Punta Toro virus, a circovirus, EIAV, bluetongue, and foot and mouth disease (FMD) viruses.

### Claim 6 (depends on 5)

The method of claim 5, wherein said virus is Ebola, Marburg, Influenza, HBV, HCV, Dengue fever, West Nile or RSV.

### Claim 7 (depends on 5)

The method of claim 5, wherein said virus is PRRS, porcine corona virus, bovine corona virus, an alphavirus, cowpox virus, Punta Toro virus, porcine circovirus, bovine circovirus, EIAV, bluetongue virus, or FMD virus.

### Claim 8 (depends on 1)

A method of treating viral infection in a mammalian cell, comprising administering an effective amount of a compound claim 1 therapeutically or prophylactically, wherein said virus is a virus of Group IV, Group V, Group VI, or Group VII.

### Claim 9 (depends on 8)

The method of claim 8, wherein said compound is R19 or R24.

### Claim 10 (depends on 5)

The method of claim 5, wherein said cell is part of a cell culture, and said compound is administered in vitro.

### Claim 11 (depends on 5)

The method of claim 5, wherein said cell is part of a mammalian host's body, and said compound is administered to said host in vivo.

### Claim 12 (depends on 8)

The method of claim 8 wherein said cell is part of a mammalian host's body, and said compound is administered to said host in vivo.

### Claim 13 (depends on 1)

A method of treating a viral infection in a mammalian host, comprising interfering with interaction between a virus causing said infection and TSG101 protein of said host, wherein said method of interfering comprises administering to said host a compound of claim 1, and wherein viral replication and budding of said virus is effected in said host in part by interaction with TSG101.

### Claim 14 (depends on 1)

A pharmaceutical composition, comprising an amount of the compound of claim 1 in a pharmaceutically acceptable carrier, wherein said compound of claim 1 is present in amounts effective to treat a mammalian host with a viral infection such that said infection is attenuated when administered to said mammalian host.

### Claim 15 (depends on 14)

The composition of claim 14, wherein said compound is R19 or R24.

### Claim 16 (depends on 1)

A method of treating viral infection in a mammal in need of same, which comprises administering a compound of claim 1 to said mammal in such fashion and amount as to interfere with post replication maturation and release of viral replicons of said virus.